Topic Paragraphs
FDA Accomplishments for the American People
FDA Seizes 7-OH Opioids to Protect American Consumers
The U.S. Food and Drug Administration, in coordination with the U.S. Department of Justice, announced today that the U.S. Marshals Service seized approximately 73,000 units of 7-hydroxymitragynine (7-OH) products—valued at roughly $1 million—from three firms in Missouri.
Read MoreRecent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
Alerting you to the latest recalls of potentially unsafe FDA-regulated products gathered from press releases and other public notices. Not all recalls have press releases or are posted on this website.
Jan 16
Olympus Expands Voluntary Recall for ViziShot 2 FLEX (19G) EBUS -TBNA Needles
Medical Devices
Jan 15
Superfoods Inc. dba Live it Up. Recalls Live it Up Super Greens Because of Possible Health Risk
Food & Beverages
Jan 14
Spring & Mulberry Expands Voluntary Recall of Select Chocolate Bars Due to Possible Salmonella Contamination
Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Encourages Development of New, Reliable Alternatives to Animal Testing in Sunscreen
FDA strongly encourages companies to continue to develop new, reliable ways to minimize animal testing.
FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity
The FDA is committed to ensuring data transparency by promoting timely registration and reporting of results information to ClinicalTrials.gov.
FDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program
ISTAND supports innovative, science-driven approaches that improve drug development and regulatory decision-making.
Recently Published Guidances
Jan 09
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
Drugs
Jan 06
Clinical Decision Support Software
Biologics, Drugs, Medical Devices
Jan 06
General Wellness: Policy for Low Risk Devices
Medical Devices